21 citations
,
June 2017 in “Case Reports in Dermatology” Reducing gefitinib dosage improved hair loss, but scarring remained.
6 citations
,
March 2024 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is effective for long-term treatment of severe alopecia areata.
January 2007 in “Frontiers in Medicine” Tofacitinib works well for treating alopecia areata, especially when combined with corticosteroids, but is less effective if the disease has lasted over 2 years.
2 citations
,
June 2019 in “Boletín médico del Hospital Infantil de México” Tofacitinib treatment is used for teenagers with alopecia areata.
24 citations
,
June 2016 in “Acta dermato-venereologica” Tofacitinib helped a young woman's severe hair loss and arthritis but not her plaque psoriasis.
August 2024 in “Indian Journal of Dermatology Venereology and Leprology”
August 2018 in “Journal of Investigative Dermatology” Tofacitinib may help regrow hair in alopecia areata patients.
May 2023 in “Reactions Weekly” January 2013 in “Reactions Weekly”
1 citations
,
April 2017 in “Journal of Investigative Dermatology” Tofacitinib may help regrow hair in severe alopecia areata, but results differ greatly between people.
December 2025 in “Biomedicines” Tyrosine kinase inhibitors for endocrine tumors often cause skin issues, requiring early management and treatment adjustments.
3 citations
,
March 2025 in “Journal of Clinical Medicine” Ritlecitinib effectively treats alopecia areata with manageable side effects.
1 citations
,
December 2012 in “Journal of dermatological science” Combining ficlatuzumab and gefitinib can cause severe scarring hair loss.
9 citations
,
August 2018 in “JAAD Case Reports” Tofacitinib can temporarily improve hair growth in alopecia universalis, but its effectiveness may decrease over time.
91 citations
,
April 2006 in “PubMed” EGFR-targeting cancer drugs can cause skin rashes and other side effects.
17 citations
,
January 2019 in “Dermatologic Therapy” Tofacitinib is effective and safe for long-term treatment of severe alopecia areata, with many patients achieving complete hair regrowth.
30 citations
,
June 2017 in “Journal of cutaneous medicine and surgery” Topical ruxolitinib failed to regrow hair in a 66-year-old with alopecia areata.
October 2024 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib and baricitinib are similarly effective for hair regrowth in severe alopecia areata.
November 2025 in “Journal of Investigative Dermatology” Ritlecitinib effectively treats severe Alopecia Areata by reducing harmful immune activity in the skin.
1 citations
,
May 2025 in “The Journal of Rheumatology” Upadacitinib may help treat difficult cases of systemic lupus erythematosus.
November 2024 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib effectively reduces severe hair loss in alopecia areata over 24 months.
April 2016 in “Journal of Investigative Dermatology” Mefloquine, an antimalarial drug, is effective in killing melanoma cells resistant to other treatments by causing lethal stress in the cells.
15 citations
,
January 2025 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib is effective and safe for treating alopecia areata, promoting significant hair regrowth.
40 citations
,
September 2018 in “Journal of the American Academy of Dermatology” Tofacitinib helped some young children with severe hair loss grow their hair back without bad side effects.
16 citations
,
August 2023 in “JAAD Case Reports” JAK inhibitors, like ruxolitinib, may effectively treat frontal fibrosing alopecia.
22 citations
,
May 2011 in “European Journal of Cancer” The drug combination was safe and showed promise in treating advanced tumors.
130 citations
,
February 2018 in “Journal of Investigative Dermatology” Tofacitinib may help treat severe hair loss, but more research is needed.
February 2025 in “International Journal of STD & AIDS” Tofacitinib can cause unusual hair growth, requiring careful monitoring and possible laser hair removal.
March 2022 in “International Journal of Trichology” Tofacitinib may be effective for treating hair loss caused by alopecia areata that doesn't respond to other treatments.
8 citations
,
August 2018 in “BMJ Case Reports” Pazopanib treatment caused rapid hair color loss, possibly indicating its effectiveness.